A NEW DAWN

Mirxes, a leading RNA technology company specializing in early cancer detection and precision medicine, today announced a US$40 million structured financing transaction with CBC Group’s R-Bridge Healthcare Fund (“R-Bridge”). This partnership will provide critical support for Mirxes’ ambitious growth and expansion into key global markets.

In a First-In-Singapore collaboration, leading RNA technology company Mirxes and PULSE TCM, a renowned provider of traditional Chinese Medicine (TCM) services, today launched the holistic “East Meets West” Community Health Screening Pilot at Bukit Gombak. Witnessed by Ms Low Yen Ling, Senior Minister of State, Ministry of Culture, Community and Youth, Ministry of Trade and Industry, Mayor of South West District and Grassroots Adviser to Bukit Gombak Grassroots Organisations, this pilot represents a novel approach towards integrating contemporary Western precision diagnostic technology with Eastern TCM wisdom, aimed at creating an integrated approach to preventive and personalised healthcare for a Healthier Singapore.

The National University Hospital (NUH) and Mirxes are proud to announce the official opening of the NUH DMOC@Biopolis, one of Singapore’s first publicprivate partnership centres for specialty molecular testing. The NUH DMOC@Biopolis is an extension of NUH’s Diagnostic Molecular Oncology Centre (DMOC) that co-locates and integrates with Mirxes’ clinical laboratory, M Diagnostics at Biopolis. The Centre was inaugurated today by Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation (NRF), Mr Heng Swee Keat.

Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S.

Mirxes Holding Company Limited, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, announced today the successful completion of its Series D funding round, securing a total of US$50 million. The funding will play a pivotal role in accelerating Mirxes’s delivery of cutting-edge cancer early detection blood tests and preventive healthcare solutions in major markets.

Singapore (NS) has received a boost ahead of a busy year for the national team, with local biotechnology company MiRXES coming on board as title sponsor of the 2023 and 2024 Nations Cup.

Photo by Lim Yaohui with The Straits Times

MiRXES signed a Memorandum of Understanding with PT ELION MEDIKA INDONESIA (PT ELION) to validate and commercialize MiRXES’s microRNA cancer blood tests for stomach and lung cancers in Indonesia, and establish CADENCE-ID, a joint project for the optimization and validation of a novel multi-cancer blood test, based on blood-borne circulating miRNA and DNA methylation biomarkers in the Indonesian population, for up to nine high incidence and high mortality cancers.

MiRXES today launches the first edition of MiRXES Translator Program, Southeast Asia’s first business and clinical advisory program backed by science that bridges post-incubation ideation and post-accelerator growth, at Singapore Week of Innovation and Technology (SWITCH). This program will accelerate revenue growth of start-ups and importantly, adoption of preventive healthcare solutions globally.

Singapore-headquartered biotech MiRXES, National University Heart Centre, Singapore (NUHCS) and National Heart Centre Singapore (NHCS) launch SPHERE (Singapore Pulmonary Hypertension Early detection with miRNA biomarkErs) study to identify biomarkers that are relevant to early detection of pulmonary hypertension with the aim to improve Asian patient outcomes and save lives.

MiRXES announced today the donation of SG$88,902 to the National University Cancer Institute, Singapore (NCIS) Cancer Fund, a sub-fund of NUHS Fund, at the closing ceremony of Let’s Ride! Singapore today, to assist less fortunate cancer patients with critical cancer treatments. This event was graced by Guest-of-Honor, Ms. Low Yen Ling, Minister of State, Ministry of Trade and Industry & Ministry of Culture, Community and Youth, and Mayor of South West District, who witnessed the cheque presentation ceremony.

Prime Minister Lee Hsien Loong spoke about Singapore’s new initiatives to attract and retain top talent to secure Singapore’s success in a post-COVID-19 world. Specific to talent in Singapore’s biomedical sector, PM Lee mentioned that home-grown scientists are now doing cutting-edge research and development, with some who have become principal researchers and others who have founded start-ups.

MiRXES is proud and humbled to be featured in the NDR 2022. We have grown from a three-man team in 2014 to over 360 staff across offices in Singapore, US, China, Japan, and several Southeast Asian countries. We have been a beneficiary of many government initiatives in talent development, technology innovation, internationalization, and scale-up, that have enabled us to develop talent and translate RNA innovation from bench to bedside, and we look forward to continue contributing to Singapore’s vibrant biotechnology ecosystem and Healthier SG initiative.